PuSH - Publication Server of Helmholtz Zentrum München

Krenn, M.* ; Sener, M.* ; Rath, J.* ; Zulehner, G.* ; Keritam, O.* ; Wagner, M. ; Laccone, F.* ; Iglseder, S.* ; Marte, S.* ; Baumgartner, M.* ; Eisenkölbl, A.* ; Liechtenstein, C.* ; Rudnik, S.* ; Quasthoff, S.* ; Grinzinger, S.* ; Spenger, J.* ; Wortmann, S.B.* ; Löscher, W.N.* ; Zimprich, F.* ; Kellersmann, A.* ; Rappold, M.* ; Bernert, G.* ; Freilinger, M.* ; Cetin, H.*

The clinical and molecular landscape of congenital myasthenic syndromes in Austria: A nationwide study.

J. Neurol. 270, 909-916 (2023)
Publ. Version/Full Text Research data DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders caused by genetic defects resulting in impaired neuromuscular transmission. Although effective treatments are available, CMS is probably underdiagnosed, and systematic clinico-genetic investigations are warranted. Methods: We used a nationwide approach to collect Austrian patients with genetically confirmed CMS. We provide a clinical and molecular characterization of this cohort and aimed to ascertain the current frequency of CMS in Austria. Results: Twenty-eight cases with genetically confirmed CMS were identified, corresponding to an overall prevalence of 3.1 per million (95% CI 2.0–4.3) in Austria. The most frequent genetic etiology was CHRNE (n = 13), accounting for 46.4% of the cohort. Within this subgroup, the variant c.1327del, p.(Glu443Lysfs*64) was detected in nine individuals. Moreover, causative variants were found in DOK7 (n = 4), RAPSN (n = 3), COLQ (n = 2), GMPPB (n = 2), CHAT (n = 1), COL13A1 (n = 1), MUSK (n = 1) and AGRN (n = 1). Clinical onset within the first year of life was reported in one half of the patients. Across all subtypes, the most common symptoms were ptosis (85.7%), lower limb (67.9%), upper limb (60.7%) and facial weakness (60.7%). The majority of patients (96.4%) received specific treatment, including acetylcholinesterase inhibitors in 20, adrenergic agonists in 11 and 3,4-diaminopyridine in nine patients. Conclusions: Our study presents the first systematic characterization of individuals with CMS in Austria, providing prevalence estimates and genotype–phenotype correlations that may help to improve the diagnostic approach and patient management.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Austria ; Chrne ; Congenital Myasthenic Syndrome ; Myasthenia
ISSN (print) / ISBN 0340-5354
e-ISSN 1432-1459
Journal Journal of Neurology
Quellenangaben Volume: 270, Issue: 2, Pages: 909-916 Article Number: , Supplement: ,
Publisher Springer
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Neurogenomics (ING)
Grants Medical University of Vienna